Q1 FY27 results: revenue and profit decline; director re-appointments approved

Revenue DeclineResults View source PDF Explain this filing

HALEOSLABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-7.7%Reaction day

₹1540.00

prior close

₹1531.50

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-9.0% vs market

Pharmaceuticals peers, median of 165sector-0.0%-7.7% vs sector

On the reaction day the stock moved 9.0 pts less than Nifty Microcap 250 and 7.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-4.7

15m

-6.2

30m

-6.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-7.7+1.3-9.0-0.0-7.7

Next day

-6.6+1.6-8.3+0.2-6.9

-4.9+1.7-6.6+0.4-5.3

-7.0+1.6-8.6+1.1-8.1

-7.2+1.5-8.7+1.2-8.4

-4.4+1.8-6.2+1.0-5.4

-3.3+2.1-5.4+0.5-3.8

15d

-2.0+3.2-5.2+0.2-2.2

-4.9+3.7-8.6+1.7-6.6

+0.6+1.1-0.5+1.2-0.6

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone revenue fell to Rs. 6,782.97 lakhs from Rs. 7,904.27 lakhs YoY, down about 14 percent. Net profit dropped to Rs. 323.78 lakhs from Rs. 515.77 lakhs. EPS at Rs. 2.75 versus Rs. 5.21. Auditor issued an unmodified limited review opinion. Board also approved re-appointment of two independent directors for a second five year term and revision of the MD's pay. 20th AGM set for September 30, 2026.

Likely market impact

Revenue and profit decline in Q1 may weigh on sentiment. Director re-appointments and AGM date are routine.